Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk recently completed a study titled ‘Efficacy ...

The company's worst days might be behind it.

Researchers adjusted for confounders like age, hypertension, cardiovascular disease, and other comorbidities. The refined results indicated GLP-1 users had a 16% lower risk of developing epilepsy ...

In an exclusive interaction with NDTV, Managing Director of Novo Nordisk India, Vikrant Shrotriya, said the launch of ...